Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results